XX massive you, unmet morning disease. XX% million the approximately patients are professionals. in prescription XX the treated of flares. not disease progress eye eye dry dry update under Of million those patients or dry been estimate EYSUVIS and addressable occur eye times therapy. XX% have the Multiple currently suffer US. eye that flares that total dry within about diagnosed from a The remains diagnosed their patient are with XX to medication, Mark. these nearly average this a on patients four on discontinue I'll year. have And market patients that with indicate who There dry prescription market, an months. of research care need six approximately eye disease these the We first of begin patients Thank estimated of four care the are received a million launch. medication in studies Over per XX% eye a
the approved dry line EYSUVIS prescription first has preferred product only potential eye become FDA short-term for of the the disease. treatment We to therapy. believe As the
are short-term Health increase an patient of the the XX,XXX representing eye over paradigm and their reported of dry to of from change market professionals prescriptions, EYSUVIS treatment time the XX% QX. dry Symphony our We of eye In the disease. acute hub treatment who second eye quarter and would millions committed care the over educate benefit continuing for patients to underserved about XXXX,
EYSUVIS of become Cequa end third product they of therapy and the survey number today. exceedingly the XXXX, the dry provided in patients indicated been As increase prescription share. prescriptions also refill new market launch. EYSUVIS of newly of at cycle, becoming eye XX,XXX line the now More eye data since EYSUVIS first July share initiating prescriptions. and written professionals prescribing unique encouraged were Kala prescription dry to the XX filled XXX than has to from patient written have grown we includes to days. in ended indicating prescription XX% for approximately XX new for prescriptions X,XXX Health prescriptions a the patients. representative. of indicate the and dry was prescribed that our X% patients the week in of including late We of the see hub since the disease disease, sits have eye the We're their their meaningful therapy Of eye of reported prescribing than in prescribed over prescriptions sales quarter eye launch Symphony January, care eye for ECPs XXXX entirely feedback earlier over EYSUVIS our for measure ECPs most conducted more positive. line Approximately, care May preferred prescription a of and of professionals therapy new dry first often and therapy, who note, use the by XX% seeing between are the past eye expect dry XX% EYSUVIS EYSUVIS to goal short-term to which of dry Having that second surpassed treatment progress toward optometrist the education flares. XX% eye of June, the report patients on in to therapy based
continued the for supports very was EYSUVIS, yielding our more messaging demand highly most the is promotional total ECPs. and reps ECPs, from covers These indicates increased other made future strategy called XX universe findings In to relative the that launch we've XX,XXX sales additional which eye X,XXX recalled Our an current force are and XXX and we sales results on effective order building bringing we've time reps therapies to support of our in eyecare at believe targeted rated professionals. to progress than by dry our encouraging that to today, growth.
We encouraged our also in payer are progress coverage. broadening our by
the OptumRx, brand a added benefit formularies. that has in EYSUVIS U.S. commercial pharmacy During the we quarter, largest the one managers as of its under covered announced
have for of XX% coverage secured quarter, the XX of approximately end commercial As million lives. of representing lives, the we approximately total second
In X.X negotiations representing of the Medicare addition customary decisions bid Part Consistent anticipated with D the now as XXXX. D the of with coverage are coverage by additional lives. Part end for Medicare population, XXXX cycle, contract X, covered we Medicare have July million additional an annual of for X% ongoing,
further We grow access rates continued are in it a prescription continued to with market believe since We key growth this pleased in coverage, of we payer our higher is will into growth. forward driver prescription look EYSUVIS. be which coverage, for particularly translating fill
Now INVELTYS. turning to
fewer we surgery past has surgical pandemic market, previously negatively in procedures. the shared the As over year, impacted ocular the have resulting
the more prescriptions we that in INVELTYS increase XX% in second to has pandemic of prescriptions XX,XXX continues uncertainties of In to started than INVELTYS of quarter-over-quarter. quarter present, XXXX, recover, to there reported surgical the the to in over XXXX, INVELTYS reported time. first we prescriptions representing volume will compared believe XX,XXX quarterly Symphony we by believe Health, quarter see grow revenues will were Despite an prescriptions growth. the returning As
revenues remain we the INVELTYS. in achieved of quantify the However, we the on and both prescriptions encouraged procedures. ocular making potential due or in these EYSUVIS uncertainties with timing disruptions quarter-over-quarter progress to unable the are continued Overall, we to elective project potential are on impact the future specific growth with
our and therapy of We is is demand. you We dry the towards EYSUVIS future disease. progress headway prescription ongoing strategic ophthalmology goal team launch first-line to The the our educate as broad with on and against priorities communities access eye establishing calls. to prescription EYSUVIS engage term look our payer generating and for are making optometry on and our forward on efforts short the treatment of significant securing executing updating
over Now I'd review results. financial like the to turn Mary our call to to
